Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling for solid tumors into Flatiron Health's OncoEMR MPI via a pilot with American Oncology Network and other community practices.
The integration aims to simplify molecular test ordering and results for up to 4,700 clinicians across 1,600 cancer care locations nationwide in the second half of the year.
Positive
- OncoEMR MPI integration to reach up to 4,700 clinicians at 1,600 locations
- Pilot access for nearly 200 American Oncology Network sites across 21 states
- Expanded availability of Haystack MRD ctDNA minimal residual disease test
- Comprehensive Genomic Profiling panels analyzing up to 530 genes for therapy response
- Alignment with strategy to simplify testing via EHR platforms like OncoEMR and Epic Aura
Negative
- None.
News Market Reaction – DGX
In the Jul 8 session, DGX declined 1.96%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 24 | Oncology test approval | Positive | +3.0% | New York State CLEP approval broadened Haystack MRD access nationwide. |
| Jun 18 | Clinical study results | Negative | -1.4% | Study highlighted widespread multidrug resistance in UTI-causing bacteria. |
| Jun 17 | Earnings release date | Neutral | -1.6% | Announcement of timing for second quarter 2026 financial results. |
| Jun 16 | ESG report release | Positive | -0.6% | Corporate Responsibility Report detailed access, workforce and sustainability gains. |
| May 19 | Dividend declaration | Positive | +1.3% | Board declared a $0.86 per share quarterly cash dividend. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions, with oncology-focused items like Haystack MRD approval drawing more favorable price responses than general corporate or scheduling updates.
Key Terms
ctdna medical
minimal residual disease medical
comprehensive genomic profiling medical
electronic health record technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD
Quest is the largest clinical reference lab to integrate oncology tests in OncoEMR using the opt-in OncoEMR Molecular Profiling Integration (MPI) ordering feature, which is designed to support the specialized test ordering requirements of comprehensive molecular tests. Once completed, the integration will enable 4,700 clinicians across the Flatiron network of 1,600 community-based cancer care locations in
"At Flatiron, we're focused on helping oncology teams get the answers they need to deliver the best possible care," said Quincy Weatherspoon, Chief Network Officer, US Point of Care, Flatiron Health. "By integrating Quest's advanced oncology services directly into existing workflows, we're making it easier for physicians to access critical testing insights without adding complexity to their day. This collaboration helps reduce administrative burden so clinicians can spend less time navigating processes and more time focused on caring for patients with cancer."
Molecular oncology testing often involves dozens or even hundreds of individual genetic biomarkers, which can complicate ordering workflows and producing long, complex results reports. The use of OncoEMR MPI will enable providers to set up accounts for Quest services faster, order tests with fewer steps, and receive easy-to-understand reports within their daily EHR workflows.
Select providers can now order and receive results from Quest using the OncoEMR MPI capability as part of a pilot program. Among the pilot customers is American Oncology Network (AON), a leader in community oncology with more than 350 providers practicing across 21 states. Nearly 200 AON sites now have access to OncoEMR MPI and can use it to order the Quest tests. Quest plans to launch the full OncoEMR MPI integration to providers nationwide in the second half of the year.
"At AON, our aim is to provide comprehensive support, ancillary services and practice management benefits to help community physicians to make cancer care better. Empowering them to use OncoEMR MPI via Quest Diagnostics is an important step in that mission," said Dr. Brian Mulherin, Medical Director at AON. "Under this arrangement, our rapidly growing network of physicians can quickly and easily order Quest's innovative cancer tests, such as Haystack MRD, to help guide patient care."
Providers in the pilot now have access to some of Quest's most innovative cancer tests, including Haystack MRD, a highly accurate circulating-tumor DNA (ctDNA) minimal residual disease (MRD) test for solid tumor cancers. In addition, the company's Comprehensive Genomic Profiling portfolio includes several panels that use advanced sequencing to identify up to 530 genes associated with therapy response, providing physicians with necessary insights to determine appropriate treatment for their patients.
"At Quest Diagnostics, we strive to provide comprehensive cancer services that empower providers to work with patients to make optimal care decisions," said Asia Chang, Vice President and General Manager, Oncology at Quest Diagnostics. "We know that positive outcomes in oncology start with excellent diagnostics, but they don't stop there. We're looking forward to providing oncologists at AON and other organizations a single-source ordering and results solution via OncoEMR MPI, as well as the world-class expertise they've come to expect from Quest."
Quest's integration of OncoEMR MPI reflects the company's strategy to make testing simpler and smarter, including through the use of specialized IT and EHR technologies. Last summer, the company began to offer its Haystack MRD test through the Epic Aura platform and now provides a range of specialized tests, from prenatal screening to Alzheimer's disease, through the platform.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in
About Flatiron Health
Flatiron Health transforms cancer care and research through a unified, global oncology engine powered by expert-validated AI and deep clinical and scientific expertise. Built from the experiences of millions of patients across the US,
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON's rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com more information, or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-now-the-largest-clinical-reference-lab-to-extend-oncology-test-access-through-oncoemr-mpi-302819760.html
SOURCE Quest Diagnostics